Saxenda Shortage; New ADA Guidance; Cheap Test for Osteoporosis Risk?
(MedPage Today) -- The shortage of weight-loss drugs now extends to liraglutide (Saxenda). (Fierce Pharma)
Compared with DPP-4 inhibitors, SGLT2 inhibitors helped reduce recurrent gout flare-ups and hospitalizations in people with type 2 diabetes... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - July 25, 2023 Category: Endocrinology Source Type: news
Evidence Weighed for Suicide/Self-Harm With Obesity Drugs Evidence Weighed for Suicide/Self-Harm With Obesity Drugs
As the EU looks into cases of suicidal thoughts and self-harm associated with the GLP-1 agonists semaglutide, and liraglutide, Novo Nordisk says it is confident of the risk-benefit profile of these agents.Medscape Medical News (Source: Medscape Pediatrics Headlines)
Source: Medscape Pediatrics Headlines - July 12, 2023 Category: Pediatrics Tags: Diabetes & Endocrinology News Source Type: news
Weight Loss Drugs and Suicide; Air Monitor Detects COVID; Fecal Bacteria at Beaches
(MedPage Today) -- Note that some links may require subscriptions.
The European Medicines Agency is investigating weight loss and diabetes drugs semaglutide (Ozempic) and liraglutide (Saxenda) over reports of suicidal thoughts. (NBC News)
Pharmacy... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 11, 2023 Category: American Health Source Type: news
More Weight Loss Drugs Are Coming, And They Could Be Even More Effective
Weight loss drugs are having a moment, owing to the fact that pharmaceutical companies have figured out how to help people lose up to double-digit percentages of their body weight and start dropping a more substantial number of pounds.
Although Ozempic, Wegovy, and Rybelsus, all Novo Nordisk products, have dominated the market in the past year, Eli Lilly has its own pipeline of obesity medications. And new data the company revealed on June 23 suggest its products could give doctors and patients a greater range of options for treating the chronic condition—including more options in the form of pills, which could make ...
Source: TIME: Health - June 26, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Drugs healthscienceclimate Source Type: news
Semaglutide Bests Liraglutide for Post-Surgery Weight Regain Semaglutide Bests Liraglutide for Post-Surgery Weight Regain
Once-weekly semaglutide produced over twice the weight loss as did daily liraglutide for people who regained weight after metabolic/bariatric surgery.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 8, 2023 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Semaglutide Better Than Liraglutide for Post-Bariatric Surgery Weight Recurrence
WEDNESDAY, June 7, 2023 -- Semaglutide is associated with superior weight loss for treating post-metabolic and bariatric surgery (MBS) weight recurrence compared with liraglutide, according to a study published in the May issue of Obesity.
Natia... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 7, 2023 Category: Pharmaceuticals Source Type: news
Obesity Drug With Swallowable Balloon Boosts Weight Loss Obesity Drug With Swallowable Balloon Boosts Weight Loss
A combination of a swallowable Allurion gastric balloon and liraglutide delivers higher weight loss (around 19% after mean 4 months) than use of separate treatments.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - May 18, 2023 Category: Primary Care Tags: Diabetes & Endocrinology News Source Type: news
Weight Loss Drug Saxenda May Make WHO List: Could Help Make It Cheaper Worldwide
Liraglutide has been approved for weight loss since 2014 by the FDA. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 31, 2023 Category: Pharmaceuticals Authors: Arianna Johnson, Forbes Staff Tags: Innovation /innovation Healthcare /healthcare Breaking breaking-news Trending Explainer Trending-Explainer Source Type: news
WHO advisers to consider whether obesity medication should be added to Essential Medicines List
Advisers to the World Health Organization will consider next month whether to add liraglutide, the active ingredient in certain diabetes and obesity medications, to its list of essential medicines. (Source: CNN.com - Health)
Source: CNN.com - Health - March 30, 2023 Category: Consumer Health News Source Type: news
Rise of slimming jabs could lead to overseas trips to remove excess skin, UK surgeons warn
Exclusive: Surgeons raise concerns that people using jabs are unaware of risks of redundant skinFrom unbearable side-effects to cravings curbed: readers on weight-loss jabsA surge in the number of people using slimming jabs to lose weight could lead to a rise in patients travelling abroad for tummy tucks or other surgery to remove excess skin, surgeons have said.Drugs such as liraglutide and semaglutide, which could help people reduce their weightby more than 10%, have been approved for use on the NHS for certain groups of people with obesity, although supplies of the latter under the brand name Wegovy have yet to arrive i...
Source: Guardian Unlimited Science - March 25, 2023 Category: Science Authors: Nicola Davis Science correspondent Tags: Drugs Health Diets and dieting Science Life and style Society UK news World news Source Type: news
Novo Nordisk notches big GLP-1 sales amid rebounding supplies, but cautions on future'periodic constraints '
With Novo Nordisk’s obesity treatment Wegovy fully back in stock in December, sales are beginning to soar, the Danish pharma reported during its annual earnings call on Wednesday. Total scripts of the glucagon-like peptide 1 (GLP-1) Wegovy topped 37,000 weekly in…#danish #wegovy #saxendaaccounted #dkk107 #larsfruergaard #karstenmunkknudsen #glp1 #nordiskreported #dkk177 #victoza (Source: Reuters: Health)
Source: Reuters: Health - February 2, 2023 Category: Consumer Health News Source Type: news
Post-Bariatric Patients See More Benefits With Semaglutide vs Liraglutide
(MedPage Today) -- SAN DIEGO -- A 1-mg dose of semaglutide (Wegovy) weekly was better at maintaining weight than 3-mg liraglutide (Saxenda) daily for patients who put on pounds after bariatric surgery, a retrospective study suggested.
Among... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - November 3, 2022 Category: Endocrinology Source Type: news
Glucose-Lowering Meds Compared for Use With Metformin in T2DM
MONDAY, Oct. 3, 2022 -- For patients with type 2 diabetes receiving metformin, the addition of glargine and liraglutide is more effective than glimepiride and sitagliptin for achieving and maintaining target glycated hemoglobin levels, while the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 3, 2022 Category: Pharmaceuticals Source Type: news
GRADE Published: Liraglutide Best for Type 2 Diabetes After Metformin GRADE Published: Liraglutide Best for Type 2 Diabetes After Metformin
The US-funded GRADE trial shows liraglutide performed best overall when added to metformin, followed by insulin glargine, with sitagliptin and glimepiride trailing. But SGLT2 inhibitors were not included in study.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 21, 2022 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
ICER Dumps on Wegovy Cost-Effectiveness; Kerendia Label Update; Synthetic Embryos?
(MedPage Today) -- The Institute for Clinical and Economic Review (ICER) said that while subcutaneous semaglutide (Wegovy) "is more effective, less burdensome, and more cost effective than liraglutide [Victoza]," it "does not meet typical cost... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - September 7, 2022 Category: Endocrinology Source Type: news
